Thus, deregulated TLR6 expression may potentiate TLR2-mediated liver inflammation in NAFLD pathogenesis, and also serve as a potential peripheral biomarker of obesity-related NASH. The gene discussed is TLR6; the disease is metabolic dysfunction-associated steatohepatitis.